Peter has over 20 years of experience in academic research and pharmaceutical lead discovery focused on the interplay of disciplines and technologies in the context understanding and modulating biological processes. He has served in leadership roles since 1995, starting with leading an academic research group at Cold Spring Harbor Laboratory and leading project teams, medicinal chemistry groups, and various initiatives. At the global level, he was heavily engaged in the Aventis Chemical Biology Initiative as the leader of the Chemical Biology Proteases platform. Throughout the years, he has been contributing to a multitude of therapeutic area projects, such as anti-thrombotics, diabetes, degenerative and inflammatory joint diseases, oncology, and most recently in cystic fibrosis. He has delivered to various novel lead and drug compounds to the Sanofi pipeline, such as a Factor Xa inhibitor and a DF508-CFTR corrector. In the process, he is involved in and drives key disciplines of Lead Generation, including automated chemistry and high throughput purification, computational chemistry and cheminformatics, as well as data management and database design and programming for LIMS, portfolio tracking, and compound registration processes.
Distinguished Scientific Fellow at Icagen